Awakn Life Sciences On Track With Phase 3 Trial To Research Substance Use Disorder
Portfolio Pulse from The Dales Report
Awakn Life Sciences Corp. (OTC:AWKNF) is moving closer to a Phase III clinical trial for the use of ketamine-assisted therapy to treat severe Alcohol Use Disorder (AUD). The company has also recently divested clinic assets in the UK to focus more on therapeutic research and intellectual property. The Phase III trial, which is the only one of its kind to receive government funding, will involve 280 participants and will be the largest of its kind.
July 26, 2023 | 6:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Awakn Life Sciences is progressing towards a Phase III clinical trial for ketamine-assisted therapy for AUD. The company's recent divestiture of UK clinic assets indicates a focus on therapeutic research and intellectual property.
The news of Awakn Life Sciences progressing towards a Phase III clinical trial for a novel therapy is positive, as it indicates potential growth and innovation in the company's product pipeline. The divestiture of UK clinic assets also suggests a strategic focus on research and development, which could lead to long-term growth. These factors could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100